Evaluation of transcutaneous carbon dioxide and saturation monitoring during fiberoptic bronchoscopy

Merve YUMRUKUZ ŞENEL¹ (ID)
Hikmet FIRAT² (ID)
Emine Bahar KURT² (ID)

¹ Clinic of Chest Diseases, Balikesir State Hospital, Balikesir, Turkey
² Balikesir Devlet Hastanesi, Göğüs Hastalıkları Kliniği, Balikesir, Türkiye

ABSTRACT

Evaluation of transcutaneous carbon dioxide and saturation monitoring during fiberoptic bronchoscopy

Introduction: The aim of the study was to assess the effects of interventions during bronchoscopy on ventilation and determine the risk factors for hyperventilation related to both interventions and patients’ demographic and clinical characteristics.

Materials and Methods: A total of 74 patients who underwent fiberoptic bronchoscopy (FOB) were included in the study. Oxygen saturation (SpO₂) and partial carbon dioxide pressure (PCO₂) were measured transcutaneously (TcSO₂ and TcPCO₂) using a sensor consisting of a probe placed on the earlobe. The demographic characteristics and basal, mean, peak and minimum values of TcSO₂ and TcPCO₂ during FOB were retrospectively analyzed and assessed in terms of the risk factors for hyperventilation.

Results: During the procedure, the device automatically recorded the TcSO₂ and TcPCO₂ values. The mean TcPCO₂ level was 37.09 ± 5.6 (27.1-60.6) mmHg. The mean increase in the TcPCO₂ level from baseline was 3.25 ± 2.12 mmHg. The mean TcSO₂ measurement was 95.9 ± 2.27 (80-100%). The measured mean and peak TcPCO₂ values were significantly higher in men. In the whole group, the patients with a history of smoking more than 20 pack-years also had significantly higher TcPCO₂ values compared to the non-smokers and light smokers. In the patients with endobronchial lesions, the decrease in the TcSO₂ level was higher during FOB (p= 0.03), and the mean difference between the lowest and mean TcSO₂ levels was significantly greater (6.2 vs 4.55%, p= 0.03).

Conclusion: Changes in ventilation during FOB have multifactorial causes. The best indicator of ventilation is PCO₂, and monitorization of PCO₂ is very
ÖZ
Fiberoptik bronkoskopi sırasında transkütanöz karbondioksit ve saturasyon monitorizasyonunun değerlendirilmesi

Giriş: Çalışmamızda, bronkoskopi sırasında uygulanan işlemlerin ventilasyon üzerine olan etkileri ile hastanın klinik ve demografik verileri ile ilişkili hypoventilasyon için risk faktörlerinin belirlenmesi amaçlanmıştır.

Materyal ve Metod: Çalışmaya fiberoptik bronkoskopi (FOB) işlemi yapılan 74 hasta dahil edilmiştir. Oksijen saturasyonu (SpO₂) ile parsiyel karbondioksit basıncı (PCO₂) transkütanöz olarak (TcSO₂ ve TcPCO₂) kulak memesine yerleştirilen bir prob aracılığı ile ölçüm yapan alet ile ölçülmuştur. Hastaların demografik özellikleri ile FOB sırasında kaydedilmiş olan bazal, ortalama, en yüksek ve en düşük TcSO₂ ve TcPCO₂ değerleri retrospektif olarak incelenmiş ve hipovertilasyona neden olabilecek risk faktörleri değerlendirilmiştir.

Bulgular: İşlem sırasında ölçülen ortala TcPCO₂ 37.09 ± 5.6 (27.1-60.6) mmHg olup, değişimi 3.25 ± 2.12 mmHg (artarak) olarak bulundu. Ortalama TcSO₂ değeri %95.9 ± 2.27 (80-100) olarak saştı. İzlenen ortala ve en düşük TcPCO₂ değerlerinin erkeklerde daha yüksek olduğu saptandı. Tüm grupta sigara içenlerin 20 paket-yıllık içme olarak TcPCO₂ değerleri, daha düşük miktarda içen ve hiç içmemişlerere göre daha yüksek bulundu. FOB'da endobronşyal lezyonu olan hastalarda TcSO₂ düzeyleri işlem sırasında daha düşük saptandı (p: 0.03); ortalama TcSO₂ ile en düşük TcSO₂ arasındaki oranda fark endobronşyal lezyonu olan hastalarda daha yüksek görüldü (%6.2 ve 4.55; p: 0.03).

Sonuç: Fiberoptik bronkoskopi sırasında gelisen ventilasyon değişiklikleri multifaktöryel bir olaydır. Ventilasyonun en iyi göstergesi PCO₂'dır ve özellikle gelisen hipovertilasyonu tahmin eden adıda PCO₂, monitorizasyonunun önemli aşındır. Yaptığımız çalışmaların sonucunda FOB işlemine girecek hastalarda gelibilecek ventilasyon problemlerini öngörmek için bazı risk faktörleri belirlenmiştir. Özellikle FOB işlemi uzun süren, endobronşyal lezyonu olan, erkek cinsiyette ve sigara içmiş hastalarda SpO₂ ile birlikte PCO₂ izleniminin yapılmasının taraflımcı önerilmektedir.

Anahtar kelimeler: Bronkoskopi; saturasyon; ventilasyon

INTRODUCTION

Fiberoptic bronchoscopy (FOB) is one of the most frequently used procedures for the visual examination of the bronchial tree for diagnostic and therapeutic purposes. FOB is a safe procedure with a complication rate of approximately 0.1% (1). However, during FOB, there is a risk for the patient to get hypoventilated due to several mechanisms, including upper airway obstruction, sedatives given before the intervention, and ventilation-perfusion mismatch related to the procedure itself (2). The best indicator for hypoventilation is partial carbon dioxide pressure (PCO₂), and arterial oxygen saturation (SaO₂) alone is not able to predict ventilation problems (3).

During FOB, although hypoxemia can be detected by an oximeter, the best indicator of ventilation, PCO₂, cannot be easily determined (1). Without any oxygen support, oxygen desaturation can suddenly occur under conscious sedation. In these cases, a pulse oximeter is a useful tool to detect ventilation abnormalities (4). In many interventional pulmonology clinics, oxygen is routinely applied to these patients during bronchoscopy. However, due to the oxygen dissociation curve, alveolar carbon dioxide pressure increases just before the patient gets significant hypoxemia. In addition, in patients under oxygen support, carbon dioxide retention can develop, and therefore the possibility of respiratory insufficiency findings must always be kept in mind (5).

Arterial blood gas analysis is the gold standard method to measure the blood carbon dioxide level, but researchers have attempted to develop alternative methods since this analysis not only has certain side effects, including pain and risk of thrombosis but it is also expensive and cannot be used to monitor the changes in values (6). Currently, carbon dioxide pressure measurements with a cutaneous digital sensor are reported to be well correlated with the results of an arterial blood gas analysis (7-9). Previous studies have investigated the transcutaneous monitoring of PCO₂ during some medical procedures. A study conducted by Heuss et al. showed increased PCO₂ levels during thoracoscopy and colonoscopy (10). In another study, patients were monitored during FOB to evaluate the feasibility of transcutaneous measurement in determining ventilation problems (1).
Different from these previous studies, we performed arterial blood gas measurements as reference to determine the accuracy and correlation of automatic transcutaneous measurements by the device.

The purpose of the study was to monitor oxygen saturation ($SpO_2$) and $PCO_2$ levels during FOB, determine the alterations in these levels under local anesthesia and sedation, assess the effects of interventions and duration of bronchoscopy on ventilation, and identify the risk factors for hypoventilation related to both interventions in line with the patients clinical and demographic characteristics. We also aimed to investigate the correlation between the $SpO_2$ and $PCO_2$ values obtained by an arterial blood gas analysis and the transcutaneous measurements of these values by a dedicated device.

**MATERIALS and METHODS**

A chart review was conducted on 81 patients aged over 18 years, who were referred to the interventional pulmonology clinic for FOB between June 2015 and June 2016. A total of 81 patients’ medical records were retrospectively analyzed. Patients with severe chronic obstructive pulmonary disease (COPD), who were found to have an $SaO_2$ value of ≤90% and/or arterial carbon dioxide pressure ($PaCO_2$) of >50 mmHg before FOB, were excluded. In addition, due to the increased hypoventilation risk, obese patients [body mass index (BMI) ≥30] were also excluded. Lastly, the patients with missing medical records were not included in the study. After applying these exclusion criteria, the sample consisted of 74 patients. The study was approved by the local ethical committee (33/02) and conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from each participant.

The blood pressure and body temperature values of the patients were evaluated before the procedure, and all were in the normal ranges. The operating room temperature was maintained at 24°C using an air conditioner.

The baseline demographic data, smoking history, comorbidities, and FOB indications were recorded. FOB was performed with an Olympus CV-200® device. The pulmonary function test was conducted using Jaeger MasterLab Pro®. We also examined the initial chest radiographs and chest computed tomography scans and noted the presence of any pleural effusion and/or mass.

Prior to FOB, we transcutaneously measured oxygen saturation and partial carbon dioxide pressure ($TcSO_2$ and $TcPCO_2$), sampled arterial blood gas simultaneously, and compared the values obtained with these two methods. The probe of the device (v-Sign-sensor; SenTec AG, Therwil, Switzerland) was placed on the earlobe of the patients to monitor and record the $TcSO_2$ and $TcPCO_2$ values continuously throughout the procedure. The mean, lowest and highest values of $TcSO_2$ and $TcPCO_2$ were calculated by the device automatically. The patients were premedicated with intramuscular 5 mg midazolam and local lidocaine before FOB. The duration of the procedure and interventions were also noted. The duration of the procedure was recorded as the time between inserting the fiberoptic bronchoscope through the nasal/oral passage and the removal of the bronchoscope.

The statistical analysis was performed employing R 3.3.2 for Windows. The quantitative data were presented as mean ± standard deviation (min-max) and the qualitative data as number and percentages. The Kolmogorov-Smirnov test revealed that the data were normally distributed; thus, we performed Student’s t-test to compare ventilation parameters between the subgroups. In order to evaluate the quality of data and accuracy, the carbon dioxide and saturation values measured by the device and the results of the arterial blood gas analysis were compared. A linear regression analysis was performed to determine the correlation between the variables, and the $R^2$ and $p$ values were interpreted. The receiver operating characteristic (ROC) curve analysis was used to determine the cut-off, area under curve (AUC), sensitivity and specificity values for the duration of FOB in predicting hypoventilation ($TcSO_2$ ≤90%). A value of $p<0.05$ was considered as statistically significant.

**RESULTS**

In this study, the data of 81 patients were collected but 7 were not found to be eligible, and therefore excluded from the study. One of these 7 patients had a BMI of ≥30 and the remaining 6 had incomplete medical records. Of the 74 patients enrolled in the study, 50 were male and 24 were female. The mean age of the patients was $61 ± 13.43$ (27-91) years. The clinical and demographic data of the patients are shown in Table 1. All the patients were treated with oxygen via cannula during the procedure, and none developed severe respiratory depression that led to the termination of the procedure. The most common
Evaluation of transcutaneous carbon dioxide and saturation monitoring during fiberoptic bronchoscopy

In order to evaluate the correlation between the device measurements and arterial blood gas analysis as the gold standard method, we took an arterial blood gas sample from the patients before FOB and simultaneously recorded the TcSO\textsubscript{2} and TcPCO\textsubscript{2} values with the sensor during the procedure. Statistically significant correlations were found between the values obtained by arterial blood gas analysis and sensor measurements (Figures 1 and 2).

The TcSO\textsubscript{2} and TcPCO\textsubscript{2} values measured and recorded by the sensor during FOB are summarized in Table 2. The mean TcPCO\textsubscript{2} level was 37.09 ± 5.6 (27.1-60.6) mmHg. The mean increase in the TcPCO\textsubscript{2} level from baseline was 3.25 ± 2.12 mmHg, and the maximum increase was 11.2 mmHg. The mean TcSO\textsubscript{2} measurement was 95.9 ± 2.27 (80-100)%, and the

### Table 1. Patients’ clinical and demographic data

| Characteristics                              |          |
|----------------------------------------------|----------|
| Age, (mean ± SD) (years) (range)            | 61.05 ± 13.43 (27-91) |
| Gender, n (%)                                |          |
| Male                                         | 50 (67.56) |
| Female                                       | 24 (32.44) |
| Smoking history, n (%)                       |          |
| Never smoked                                 | 27 (36.49) |
| <20 pack-years                               | 9 (12.16)  |
| ≥20 pack-years                               | 38 (51.35) |
| Arterial blood gas values (mean ± SD)        |          |
| PaCO\textsubscript{2} (mmHg)                 | 37.22 ± 4.66  |
| SaO\textsubscript{2} (%)                    | 96.94 ± 2.46  |

SD: Standard deviation, PaCO\textsubscript{2}: Arterial carbon dioxide pressure, SaO\textsubscript{2}: Arterial oxygen saturation.

Figure 1. Scatter plot showing the correlation between SaO\textsubscript{2} and TcSO\textsubscript{2} (p< 0.001, r= 0.25). A linear regression analysis was performed to determine the correlation between TcSO\textsubscript{2} and SaO\textsubscript{2}.

| Characteristics                              |          |
|----------------------------------------------|----------|
| Arterial blood gas values (mean ± SD)        |          |
| PaCO\textsubscript{2} (mmHg)                 | 37.22 ± 4.66  |
| SaO\textsubscript{2} (%)                    | 96.94 ± 2.46  |

SD: Standard deviation, PaCO\textsubscript{2}: Arterial carbon dioxide pressure, SaO\textsubscript{2}: Arterial oxygen saturation.
mean decrease in TC\textsubscript{SO\textsubscript{2}} during the procedure was 5.11 ± 3.17 (1-15)\%.

An analysis was performed to determine the risk factors for developing hypoventilation, and the data are summarized in Table 3 and 4. The mean and peak TC\textsubscript{PCO\textsubscript{2}} levels were significantly higher in males than in females (p= 0.0027 and p= 0.001, respectively). Furthermore, the patients with a smoking history of more than 20 pack-years also had significantly higher TC\textsubscript{PCO\textsubscript{2}} levels compared to the non-smokers and light smokers (p= 0.001). However, there was no significant relationship between the ventilation parameters and coexistent pleural effusion and COPD history. In the patients with endobronchial lesions, the decrease in the TC\textsubscript{SO\textsubscript{2}} level during FOB was higher compared to those without endobronchial lesions (p= 0.03), and the mean difference between the lowest and mean TC\textsubscript{SO\textsubscript{2}} levels was significantly greater in the patients with endobronchial lesions (6.2 vs 4.55\%, p= 0.03).

The ROC analysis revealed that the optimal cut-off value for FOB duration in predicting hypoventilation was 15 minutes (AUC = 0.669, 95\% confidence interval: 0.546-0.791) with a sensitivity of 89.7\% and specificity of 33\%. We determined that the FOB duration being longer than 15 minutes and the presence of complex interventions, such as biopsy and brushing were associated with lower TC\textsubscript{SO\textsubscript{2}} levels (p= 0.009 and p= 0.04, respectively). Although the association between the forced expiratory volume in one second (FEV\textsubscript{1}) and ventilation parameters was statistically non-significant, the forced vital capacity was significantly related with lower peak and mean TC\textsubscript{PCO\textsubscript{2}} values (p= 0.01 and p= 0.03).

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
 & Tc\textsubscript{PCO\textsubscript{2}} (mmHg) & Tc\textsubscript{SO\textsubscript{2}} (%) \\
\hline
Mean* & 37.09 ± 5.6 & Mean* & 95.9 ± 2.27 \\
Peak & 60.6 & Lowest & 80 \\
Difference* & 3.25 ± 2.12 & Difference* & 5.11 ± 3.17 \\
\hline
\end{tabular}
\caption{Tc\textsubscript{SO\textsubscript{2}} and Tc\textsubscript{PCO\textsubscript{2}} values measured by the sensor during bronchoscopy}
\end{table}

*Values are expressed as means ± standard deviation.
Tc\textsubscript{SO\textsubscript{2}}: Transcutaneously measured saturation, Tc\textsubscript{PCO\textsubscript{2}}: Transcutaneously measured carbon dioxide.

**Figure 2.** Scatter plot showing the correlation between Pa\textsubscript{CO\textsubscript{2}} and Tc\textsubscript{PCO\textsubscript{2}} (p< 0.001, r= 0.25). A linear regression analysis was performed to determine the correlation between Tc\textsubscript{PCO\textsubscript{2}} and Pa\textsubscript{CO\textsubscript{2}}.
DISCUSSION

The use of non-invasive methods to determine the SpO₂ and PCO₂ levels compared to the arterial blood gas analysis has numerous advantages, including less complications and continuous recording of measurements. In particular, the risk of hypoventilation is increased in interventions with a long duration. Hypoventilation during interventions is a multifactorial issue that can occur through several mechanisms, including upper airway obstruction, alveolar hypoventilation secondary to sedatives given just before the procedure, and ventilation-perfusion mismatch caused by the intervention itself (2). Current guidelines recommend sedation before bronchoscopy in order to improve patient comfort and reduce complications (11). However, the use of sedatives alone or in combination can cause hypoventilation. In our clinic, we premedicate patients only with low dose of midazolam and local lidocaine. Obesity is another important reason for hypoventilation, and therefore we excluded patients with a BMI of ≥30 from our sample. The best indicator of hypoventilation is an increased PaCO₂ level, and SaO₂ alone is not sufficient to assess ventilation (3).

The British Thoracic Society (BTS) guidelines warn clinicians to be careful about respiratory insufficien-

| Table 3. Mean and maximum TcPCO₂ values according to the risk groups |
|-----------------------------|--------|-----------------------------|--------|
|                            | Mean TcPCO₂ (mmHg) | p   | Maximum TcPCO₂ (mmHg) | p   |
| Age                        |                   |     |                           |     |
| ≥65 y                      | 37.4 ± 4.8        | 0.90| 40.2 ± 5.3                | 0.71|
| <65 y                      | 36.9 ± 6          |     | 40.4 ± 7                  |     |
| Gender                     |                   |     |                           |     |
| Female                     | 34.2 ± 3.8        | 0.0027*| 37.2 ± 3.9                | 0.001*|
| Male                       | 38.5 ± 5.8        |     | 41.8 ± 6.8                |     |
| Smoking (pack-years)       |                   |     |                           |     |
| ≤20                        | 35.2 ± 4.5        | 0.001*| 38 ± 4.9                  | 0.002*|
| >20                        | 39 ± 6            |     | 42.6 ± 6.9                |     |
| COPD                       |                   |     |                           |     |
| Yes                        | 36.1 ± 4.9        | 0.5 | 39.4 ± 4.9                | 0.43|
| No                         | 37.4 ± 5.8        |     | 40.6 ± 6.7                |     |
| FEV₁ (%)                   |                   |     |                           |     |
| ≥80                        | 35.7 ± 4.8        | 0.43| 39 ± 5.7                  | 0.38|
| <80                        | 39.1 ± 5.6        |     | 42.5 ± 6.8                |     |
| FVC (%)                    |                   |     |                           |     |
| ≥80                        | 36 ± 4.6          | 0.03*| 39 ± 5.2                  | 0.01*|
| <80                        | 38.7 ± 5.9        |     | 42.2 ± 7.1                |     |
| Pl. effusion               |                   |     |                           |     |
| Yes                        | 37.8 ± 6.5        | 0.75| 40.7 ± 8.2                | 0.52|
| No                         | 36.7 ± 6          |     | 40.2 ± 8.8                |     |
| Duration                   |                   |     |                           |     |
| ≤15 min                    | 36.5 ± 5.3        | 0.23| 39.2 ± 5.8                | 0.32|
| >15 min                    | 37.5 ± 5.8        |     | 41 ± 6.7                  |     |
| EBL                        |                   |     |                           |     |
| Yes                        | 37.9 ± 5.4        | 0.33| 41.3 ± 5.5                | 0.36|
| No                         | 36.7 ± 5.7        |     | 39.8 ± 6.8                |     |
| Intervention               |                   |     |                           |     |
| Complex                    | 37.4 ± 5.7        | 0.33| 40.8 ± 6.4                | 0.48|
| Simple                     | 36.4 ± 5.4        |     | 39.3 ± 6.3                |     |

* Statistically significant.
Values are expressed as mean ± standard deviation. T-test was performed to compare the ventilation parameters between the subgroups.
Tc: Transcutaneously measured values, y: Years, EBL: Endobronchial lesion, FEV₁: Forc, forced expiratory volume in 1 second, FVC: Forced vital capacity.
cy signs during bronchoscopy, especially in oxygen supported cases in which carbon dioxide retention can develop even if \( \text{SaO}_2 \) is within the confident interval (5). The highest tolerable \( \text{PaCO}_2 \) level during FOB is not known. In patients with severe COPD, sedation can cause carbon dioxide retention (12). Respiratory complications associated with FOB are more common in patients with severe COPD (13). In our study, 16 patients had COPD, and 11 of these patients were found to have <50% \( \text{FEV}_1 \). However, there was no statistically significant difference between the patients with and without COPD in terms of ventilation parameters. This may be because before the procedure, we treated these patients with nebulizers in order to prevent possible bronchospasm. In addition, as the BTS guidelines recommend, we performed continuous monitoring of the patients and provided controlled oxygen support throughout FOB.

Since an arterial blood gas analysis shows the instant values of ventilation, monitoring of ventilation during the whole procedure is not possible. Therefore, recently, one of the main goals is to develop new techniques to monitor \( \text{PCO}_2 \) levels. The end-tidal carbon dioxide pressure measurement is another technique to monitor ventilation, which is well correlated with \( \text{PaCO}_2 \) in intubated patients (10,14).

| Table 4. Mean and minimum TcSO\(_2\) values according to the risk groups |
|-----------------------------------------------|
| **Mean TcPCO\(_2\) (mmHg)** | **p** | **Maximum TcPCO\(_2\) (mmHg)** | **p** |
| Age | | | |
| ≥65 y | 95.7 ± 2.7 | 0.44 | 89.9 ± 4.5 | 0.14 |
| <65 y | 96.1 ± 2 | 91.4 ± 4.1 | |
| Gender | | | |
| Female | 95.3 ± 2.5 | 0.08 | 90 ± 4.5 | 0.73 |
| Male | 96.3 ± 2.1 | 91.2 ± 4.2 | |
| Smoking (pack-years) | | | |
| ≤20 | 95.9 ± 2.3 | 0.84 | 90.9 ± 4.3 | 0.91 |
| >20 | 96 ± 2.3 | 90.8 ± 4.3 | |
| COPD | | | |
| Yes | 95 ± 2.7 | 0.07 | 89 ± 5.5 | 0.05 |
| No | 96.2 ± 2.1 | 91.3 ± 3.8 | |
| FEV\(_1\) (%) | | | |
| ≥80 | 95.4 ± 2 | 0.06 | 90.4 ± 3.7 | 0.71 |
| <80 | 96.1 ± 2.3 | 90.7 ± 4.7 | |
| FVC (%) | | | |
| ≥80 | 95.5 ± 2.3 | 0.38 | 90.6 ± 4 | 0.59 |
| <80 | 96 ± 2.1 | 90.5 ± 4.5 | |
| Pl. effusion | | | |
| Yes | 95.7 ± 2.4 | 0.65 | 90.1 ± 4.8 | 0.37 |
| No | 95.8 ± 2.2 | 90.8 ± 4.4 | |
| Duration | | | |
| ≤15 min | 96.3 ± 1.8 | 0.15 | 92.2 ± 4 | 0.009* |
| >15 min | 95.7 ± 2.5 | 90 ± 4.3 | |
| EBL | | | |
| Yes | 95.3 ± 2.9 | 0.01* | 89.1 ± 5.4 | 0.03* |
| No | 96.2 ± 1.8 | 91.7 ± 3.4 | |
| Intervention | | | |
| Complex | 95.6 ± 2.4 | 0.04* | 90.3 ± 4.5 | 0.13 |
| Simple | 96.7 ± 1.9 | 91.9 ± 3.9 | |

* Statistically significant.

Values are expressed as mean ± standard deviation. T-test was performed to compare the ventilation parameters between the subgroups.

Tc: Transcutaneously measured values, y: years, EBL: Endobronchial lesion, FEV\(_1\): forced expiratory volume in 1 second, FVC: forced vital capacity.
However, during endoscopic procedures, some factors, including involuntary patient movements, cough, and ventilation switch between the nose and mouth can cause artefacts in end-tidal carbon dioxide values or false interpretations (10). In 1951, it was shown that when the skin reached the highest tolerable temperature (45°C), the skin blood flow increased and the surface oxygen level reached the arterial oxygen level (15). Since then, some transcutaneous devices have been developed to monitor carbon dioxide and oxygen level simultaneously using small clips placed on the distal parts of the body, such as the earlobes (16). Studies have demonstrated that transcutaneously measured TcPCO$_2$ values are well correlated with PaCO$_2$ values measured by an arterial blood gas analysis (17-19). Similarly, in our study, the statistical analysis revealed a correlation between the TcPCO$_2$ values measured by the sensor and the arterial blood PaCO$_2$ levels.

Previous studies monitoring PCO$_2$ and SpO$_2$ during FOB showed that the PCO$_2$ levels increased during this procedure (1,3). The authors interpreted this increase in PCO$_2$ levels as an early sign of respiratory depression. In our study, we found that the mean and peak TcPCO$_2$ values were higher in men compared to women (p = 0.0027). Certain factors, including a smoking history and presence of a mass on imaging are more common in men, which must may also be the reason why respiratory depression signs are more common in this group. Smoking is associated with the worsening of ventilation and some respiratory symptoms that are increasing with the number of pack-years (20). In the present study, it was found that the mean TcPCO$_2$ was higher in the patients with a history of smoking more than 20 pack-years (p = 0.002).

According to our results, the patients with masses in their imaging findings (n = 36) had statistically significantly lower mean and lowest TcSO$_2$ values than those without any mass (p = 0.01 and p = 0.008, respectively). It is also notable that the difference between the mean and lowest TcSO$_2$ values was higher in the patients with endobronchial lesions than those without these lesions (6.20 ± 3.50 vs. 4.55 ± 2.87%, p = 0.03). Credle et al. determined that major complications and mortality rates of FOB were fairly rare at 0.08 and 0.01%, respectively. Most cases seem to be preventable, and therefore proper monitization is essential. Premedication and topical anesthesia dosage must be restricted in order to avoid respiratory depression or systemic toxicity (21).

In 2006, Chhajed et al. assessed the association between the FOB duration and PCO$_2$ levels. The authors reported that there was no significant relationship between the FOB duration and increased PCO$_2$ levels (3). According to our results, although the TcPCO$_2$ values were higher in the patients whose procedure lasted longer than 15 minutes, the difference was statistically non-significant (41.01 vs. 39.24 mmHg, p = 0.32). In the patients with FOB duration of more than 15 minutes, the mean TcSO$_2$ was lower, and the difference between the mean and minimum TcSO$_2$ values was higher (p = 0.009 and p = 0.01, respectively).

**CONCLUSION**

It is not easy to detect patients at higher risk of developing hypoventilation during FOB. The pathophysiology underlying hypoventilation during FOB is multifactorial. PCO$_2$ remains the best indicator of ventilation, and it is clear that monitization of PCO$_2$ is essential to detect hypoventilation.

Our results support the feasibility of the transcutaneous measurements of PCO$_2$ and SpO$_2$. We identified male gender, presence of endobronchial lesions, heavy smoking, and longer FOB duration (>15 min) as risk factors for developing hypoventilation during the procedure. We consider it essential that patients with these risk factors are monitored for SpO$_2$ and PCO$_2$ during FOB. However, larger and prospective studies are needed to confirm our results.

**Ethical Committee Approval:** The approval for this study was obtained from institutional review board committee of University of Health Sciences, Diskapi Research and Training Hospital, Ankara (Decision no: 33.02 Date: 12.12.2016).

**CONFICT of INTEREST**

The authors of this manuscript declare that they have no conflict of interest.

**AUTHORSHIP CONTRIBUTIONS**

Concept/Design: MYS, HF
Analysis/Interpretation: MYS
Data Acquisition: MYS
Writing: MYS
Critical Revision: HF, EBK
Final Approval: MYS, HF, EBK
REFERENCES

1. Evans E, Ganeshalingam K, Ebden P. Changes in oxygen saturation and transcutaneous carbon dioxide and oxygen levels in patients undergoing fibreoptic bronchoscopy. Respir Med 1998; 92(5): 739-42.

2. Chhajed PN, Glanville AR. Management of hypoxemia during flexible bronchoscopy. Clin Chest Med 2003; 24(3): 511-6.

3. Chhajed PN, Rajasekaran R, Kaegi B, Chhajed TP, Plimlin E, Leuppi J, et al. Measurement of combined oximetry and cutaneous capnography during flexible bronchoscopy. Eur Respir J 2006; 28(2): 386-90.

4. Fu ES, Downs JB, Schweiger JW, Miguel RV, Smith RA. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest 2004; 126(5): 1552-8.

5. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013; 68 Suppl 1: i1-i44.

6. Gursel G. Respiratory monitoring during mechanical ventilation: II. Tuberk Toraks 2003; 51(1): 100-6.

7. Sanders MH, Kern NB, Costantino JP, Stiller RA, Strollo PJ, Studnicki KA, et al. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. Chest 1994; 106(2): 472-81.

8. Stege G, Van Den Elshout Fj, Heijdra YF, Van De Ven MJ, Dekhuijzen PR, Vos Pj, Studnicki KA, et al. Accuracy of transcutaneous carbon dioxide tension measurements during cardiopulmonary exercise testing. Respir 2008; 78(2): 147-53.

9. Urbano J, Cruzado V, Lopez-Herce J, Del Castillo J, Bellon JM, Carrillo A. Accuracy of three transcutaneous carbon dioxide monitors in critically ill children. Pediatric Pulmonol 2010; 45(5): 481-6.

10. Heuss LT, Chhajed PN, Schnieper P, Hirt T, Beglinger C. Combined pulse oximetry/cutaneous carbon dioxide tension monitoring during colonoscopies: pilot study with a smart ear clip. Digestion 2004; 70(3): 152-8.

11. Kar Kurt O, Talay F, Kargi A, Yasar Z, Tug T. Sedation for fiberoptic bronchoscopy: review of the literature. Tuberk Toraks 2015; 63(1): 42-7.

12. Committee BTSBG. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56(suppl 1): i1-i21.

13. Bellinger CR, Khan I, Chatterjee AB, Haponik EF. Bronchoscopy safety in patients with chronic obstructive lung disease. J Bronchology Interv Pulmonol 2016; 24(2): 98-103.

14. Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. Academic emergency medicine: Soc Emerg Med 2002; 9(4): 275-80.

15. Baumberger J, Goodfriend R (eds). Determination of arterial oxygen tension in man by equilibration through intact skin. Federation Amer Soc Exp Biol Med 20814-3998. Federation Proceedings; 1951, 9650 Rockville Pike, Bethesda.

16. Bernet-Buettiker V, Ugarte MJ, Frey B, Hug MI, Baenziger O, Weiss M. Evaluation of a new combined transcutaneous measurement of PCO2/pulse oximetry oxygen saturation ear sensor in newborn patients. Pediatrics 2005; 115(1): e64-e8.

17. Storre JH, Magnet FS, Dreher M, Windisch W. Transcutaneous monitoring as a replacement for arterial PCO2 monitoring during nocturnal non-invasive ventilation. Respir Med 2011; 105(1): 143-50.

18. Chhajed PN, Kaegi B, Rajasekaran R, Tamm M. Detection of hypoventilation during thoracoscopy: combined cutaneous carbon dioxide tension and oximetry monitoring with a new digital sensor. Chest 2005; 127(2): 585-8.

19. Chhajed PN, Langewitz W, Tamm M. (Un) explained hyperventilation. Respiration 2006; 73(6): 825.

20. Isabel U, Alberto C, Maria QJ, Nerea M, Xavier B, Jordi S. Smoking habit, respiratory symptoms and lung function in young adults. Eur J Health 2005; 15(2): 160-5.

21. Credle Jr WF, Smiddy JF, Elliott RC. Complications of fiberoptic bronchoscopy 1–3. Am Rev Respir Dis 1974; 109(1): 67-72.